Home / Health / Cancer Vaccine Trial Begins for Lynch Syndrome
Cancer Vaccine Trial Begins for Lynch Syndrome
5 Aug
Summary
- A new vaccine trial is underway to protect those at higher risk of cancer.
- Lynch Syndrome affects 1 in 300 people, increasing cancer risk significantly.
- The trial is a collaboration between the University of Oxford and Moderna.
A significant vaccine trial has begun, aiming to protect individuals diagnosed with Lynch Syndrome, an inherited condition carrying a substantial cancer risk. This syndrome affects approximately one in 300 people, potentially leading to an 80% lifetime chance of developing certain cancers. In the UK alone, it is estimated that over 175,000 individuals have this condition, often managed through regular screenings and surgical interventions.
The development of this preventative vaccine is a joint venture between the University of Oxford and the renowned biotech company Moderna. The first participant in this crucial study is Sarah Ewart, a 53-year-old software developer from Oxford who learned of her diagnosis 24 years ago. She expressed optimism that the vaccine could be life-changing for those at elevated cancer risk by enabling their bodies to identify and neutralize early cancerous cells.
